{"filing":{"accession_number":"0001628280-26-046136","cik":"0001396814","ticker":"PCRX","company_name":"Pacira BioSciences, Inc.","form":"8-K","filing_date":"2026-06-30","report_date":null,"primary_document":"pcrx-20260628.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1396814/000162828026046136/pcrx-20260628.htm"},"events":[{"id":14832,"run_id":13223,"accession_number":"0001628280-26-046136","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.97,"summary":"Pacira entered into a Stock and Asset Purchase Agreement on June 28, 2026, to divest its iovera® business and wholly owned subsidiary Pacira CryoTech to Zimmer Biomet for up to $140 million ($70 million upfront plus up to $70 million in contingent revenue-based milestone payments through 2031), representing approximately 8% of the company's workforce and advancing its strategic transition into a biopharmaceutical company.","company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":[{"id":12390,"accession_number":"0001628280-26-046136","item_number":"1.01","item_title":"Entry Into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Pacira entered into a Stock and Asset Purchase Agreement on June 28, 2026, to divest its iovera® business and the wholly owned subsidiary Pacira CryoTech to Zimmer Biomet for up to $140 million ($70 million upfront plus up to $70 million in contingent revenue-based milestone payments through 2031). This is a material disposition of a significant business line representing approximately 8% of the company's workforce, explicitly disclosed under Item 1.01 as a \"Material Definitive Agreement\" and characterized as advancing the company's strategic transition into a biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T11:32:41.831724+00:00","company_name":"","ticker":null,"filing_date":""},{"id":12391,"accession_number":"0001628280-26-046136","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Pacira announced entry into a Purchase Agreement to divest its iovera® business to Zimmer Biomet for up to $140 million ($70 million upfront plus up to $70 million in milestone payments). This is a material disposition of a business unit that aligns with the company's strategic transition and will be used to strengthen the balance sheet through debt paydown. The transaction is a clear M\u0026A activity—specifically a divestiture—that would materially affect investor assessment of the company's portfolio and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T11:32:41.831724+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12390,"accession_number":"0001628280-26-046136","item_number":"1.01","item_title":"Entry Into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Pacira entered into a Stock and Asset Purchase Agreement on June 28, 2026, to divest its iovera® business and the wholly owned subsidiary Pacira CryoTech to Zimmer Biomet for up to $140 million ($70 million upfront plus up to $70 million in contingent revenue-based milestone payments through 2031). This is a material disposition of a significant business line representing approximately 8% of the company's workforce, explicitly disclosed under Item 1.01 as a \"Material Definitive Agreement\" and characterized as advancing the company's strategic transition into a biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T11:32:41.831724+00:00","company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","filing_date":"2026-06-30"},{"id":12391,"accession_number":"0001628280-26-046136","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Pacira announced entry into a Purchase Agreement to divest its iovera® business to Zimmer Biomet for up to $140 million ($70 million upfront plus up to $70 million in milestone payments). This is a material disposition of a business unit that aligns with the company's strategic transition and will be used to strengthen the balance sheet through debt paydown. The transaction is a clear M\u0026A activity—specifically a divestiture—that would materially affect investor assessment of the company's portfolio and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T11:32:41.831724+00:00","company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","filing_date":"2026-06-30"}]}